Cargando…
Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial
BACKGROUND: In the phase 2/3 BLAZE-1 trial, bamlanivimab and etesevimab together reduced coronavirus disease 2019 (COVID-19)–related hospitalizations and any-cause mortality in ambulatory patients. Herein, we assess the impact of bamlanivimab and etesevimab treatment on the severity and length of sy...
Autores principales: | Chen, Peter, Behre, Gerhard, Hebert, Corey, Kumar, Princy, Farmer Macpherson, Lisa, Graham-Clarke, Peita Louise, De La Torre, Inmaculada, Nichols, Russell M, Hufford, Matthew M, Patel, Dipak R, Naegeli, April N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045956/ https://www.ncbi.nlm.nih.gov/pubmed/35493124 http://dx.doi.org/10.1093/ofid/ofac172 |
Ejemplares similares
-
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load
por: Dougan, Michael, et al.
Publicado: (2021) -
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
por: Dougan, Michael, et al.
Publicado: (2021) -
A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2
por: Nathan, Ramesh, et al.
Publicado: (2021) -
500. A Real-World Cohort Study of Bamlanivimab Versus Bamlanivimab-Etesevimab for Non-severe COVID-19
por: Monday, Lea, et al.
Publicado: (2021) -
Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection
por: Bavaro, DF, et al.
Publicado: (2022)